American clinical-stage biotechnology company Longeveron Inc. (NASDAQ: LGVN) announced on Wednesday that it has received a new United States patent for its proprietary mesenchymal stem cell treatment.

The patent, issued by the United States Patent and Trademark Office, covers methods of administering isolated allogeneic mesenchymal stem cells to patients with aging-related frailty. It grants protection until 2038, with potential for further extensions based on regulatory exclusivity.

Aging-related frailty is a syndrome affecting older adults, characterised by weakness, reduced physical activity, slowed motor performance, exhaustion, and unintended weight loss. The condition, which currently has no approved therapies, is linked to chronic inflammation, or "inflammaging," thought to play a role in multiple age-associated diseases.

Longeveron's lead candidate, laromestrocel, has shown positive early results in Phase 1 and Phase 2 clinical trials focused on improving physical performance in frailty patients. The therapy is derived from mesenchymal stem cells taken from the bone marrow of healthy young donors and is designed to support tissue repair and immune regulation.

According to the company, laromestrocel's multi-functional mechanisms may enable anti-inflammatory and regenerative effects, suggesting broad potential across rare and aging-related conditions.